4
Changes in Ownership
Pacira BioSciences, Inc. Filed Acc 0001628280-26-026669
Chief Financial Officer sold 12,059 shares at an average $25.09 ($302,598)
- Chief Financial Officer acquired 12,059 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Cross Shawn Chief Financial Officer | 2026-04-20 | Option exercise 10b5-1 | +7,714 | $16.45 | $126,895 | 113,055 | D |
| Cross Shawn Chief Financial Officer | 2026-04-20 | Sale 10b5-1 | −7,714 | $25.14 | $193,930 | 105,341 | D |
| Cross Shawn Chief Financial Officer | 2026-04-21 | Option exercise 10b5-1 | +2,845 | $16.45 | $46,800 | 108,186 | D |
| Cross Shawn Chief Financial Officer | 2026-04-21 | Sale 10b5-1 | −2,845 | $25.01 | $71,153 | 105,341 | D |
| Cross Shawn Chief Financial Officer | 2026-04-22 | Option exercise 10b5-1 | +1,500 | $16.45 | $24,675 | 106,841 | D |
| Cross Shawn Chief Financial Officer | 2026-04-22 | Sale 10b5-1 | −1,500 | $25.01 | $37,515 | 105,341 | D |
| Derivatives | |||||||
| Cross Shawn Chief Financial Officer | 2026-04-20 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −7,714 | 167,286 | D | ||
| Cross Shawn Chief Financial Officer | 2026-04-21 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −2,845 | 164,441 | D | ||
| Cross Shawn Chief Financial Officer | 2026-04-22 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −1,500 | 162,941 | D | ||
| Open-market sales · 12,059 sh · avg $25.09 · $302,598 | |||||||
Loading xslF345X06/wk-form4_1776902593.xml…